Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.38 |
| ▸ | SGK1 | O00141 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682468 | 0.85 | TRPV4 (0.43) | TRPV4ALDH1A1HTTKDM4ECYP3A4 | |
| SCHEMBL12327903 | 0.83 | SGK1 (0.41) | ALDH1A1HTTKDM4ECYP3A4CYP2D6 | |
| SCHEMBL31650255 | 0.81 | KDM4E (0.47) | ALDH1A1HTTKDM4ECYP3A4CYP2D6 | |
| SCHEMBL1726020 | 0.81 | KDM4E (0.47) | ALDH1A1HTTKDM4ECYP3A4CYP2D6 | |
| SCHEMBL1941895 | 0.79 | VCAM1 (0.47) | TRPV4ALDH1A1SLC22A12SGK1 | |
| SCHEMBL20872675 | 0.78 | MAOB (0.40) | TRPV4ALDH1A1HTTSLC22A12 | |
| SCHEMBL12777966 | 0.78 | TRPV4 (0.42) | TRPV4ALDH1A1HTTSLC22A12 | |
| SCHEMBL14775214 | 0.77 | GLA (0.43) | TRPV4ALDH1A1KDM4ESLC22A12AR | |
| SCHEMBL29627448 | 0.76 | TRPV4 (0.42) | TRPV4ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL2426442 | 0.76 | TRPV4 (0.42) | TRPV4ALDH1A1KDM4EPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4147700-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | LQT Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| US-11485721-B2 | Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (DE) | 2022-11-01 | — | — | US | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20200339529-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) | 2020-10-29 | — | — | US | disclosed |
| EP-3713910-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2020-09-30 | — | — | EP | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019101679-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL INSTITUT (HKI) (DE) | 2019-05-31 | — | — | WO | disclosed |
| EP-3486229-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007071452-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
| EP-0906091-B1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-0906091-A4 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-0906091-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5891909-A | Amidinohydrazones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1997036580-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485721-B2 | Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses | CBR3, POR, CYP2F1 | TRPV4 4156/4885ALDH1A1 809/4885HTT 3624/4885 |
| US-20200339529-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | CBR3, POR, CYP2F1 | TRPV4 4156/4885ALDH1A1 809/4885HTT 3624/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | TRPV4 4041/4885ALDH1A1 3985/4885HTT 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.